Axel Hoos
-
GlaxoSmithKline Pays $60M to Develop Adaptimmune Therapeutics’ Cancer Treatment
GlaxoSmithKline has agreed to pay up to $61 million to license, research, and develop a cancer treatment based on Adaptimmune…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
